本實驗以肺癌類幹細胞為模式研究 teroxirone 與中草藥抑制細胞生長的效果。之前研究已經知道低劑量的 teroxirone 具有抑制人類非小細胞肺癌 (NSCLC) 細胞生長之效果，在這次實驗中利用 BrdU assay 、反轉錄聚合酶連鎖反應、西方墨點法及 TUNEL assay 證實此藥物會藉由引起細胞凋亡而抑制 NSCLC 細胞之癌類幹細胞的生長，並且會抑制幹細胞標記分子的表現。另一部分，已經有報告指出多種中草藥具有抗癌效力，而本實驗篩選出中草藥 A 可以抑制 H1975 (EGFR 雙重突變的肺癌細胞株) 貼附型細胞及癌類幹細胞的生長，利用流式細胞儀、反轉錄聚合酶連鎖反應及西方墨點法證實此中藥會誘使 H1975 細胞凋亡，並且也會抑制幹細胞標記分子的表現。

This study is based on the lung cancer stem-like cells model, which may be higher metastasis and resistance. To identify teroxirone and Chinese medicine herbs (CMH) that can potentially eradicate lung cancer stem-like cells, we will confirm the platform of lung cancer stem-like cells established. Previous report showed that teroxirone inhibited growth of human non-small-cell-lung-cancer cells (NSCLC) at low concentrations. Using BrdU assay, RT-PCR, western blot and TUNEL assay, this study showed that the drug reduced the cells proliferation by apoptosis and inhibited expression of the related stemness markers. The next part, Some recent studies showed that many CMHs possessed effects of anticancer. This study showed that CMH A inhibits growth of H1975 (mutant EGFR-L858R/T790M) monolayer and spheroid cells. Using flow cytometry, RT-PCR and western blot, this study confirmed that this CMH induced apoptosis and inhibited expression of the related stemness markers in H1975 cells.

1. Center for Disease Control, R.O.C. (Taiwan).
http://health99hpagovtw/TXT/HealthyHeadlineZone/HealthyHeadlineDetaiaspx?TopIcNo=6798.
2. Gibbons DL, Byers LA, Kurie JM (2014) Smoking, p53 mutation, and lung cancer. Mol Cancer Res 12: 3-13.
3. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, et al. (2007) Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25: 5570-5577.
4. Sher T, Dy GK, Adjei AA (2008) Small cell lung cancer. Mayo Clin Proc 83: 355-367.
5. Baldi A, De Luca A, Esposito V, Campioni M, Spugnini EP, et al. (2011) Tumor suppressors and cell-cycle proteins in lung cancer. Patholog Res Int 2011: e 605042.
6. Tan C, Xu HY, Zhang CY, Zhang H, Chen CM, et al. (2011) Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer. Arch Med Res 42: 669-676.
7. Little AG (2006) No nodes is good nodes. Ann Thorac Surg 82: 4-5.
8. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.
9. Willers H, Dahm-Daphi J, Powell SN (2004) Repair of radiation damage to DNA. Br J Cancer 90: 1297-1301.
10. Brosseau S, Oulkhouir Y, Naltet C, Zalcman G (2015) Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC. Bull Cancer 102: S27-33.
11. Kim JW, Kim WC, Cho JH, Kim DS, Shim KW, et al. (2012) A multimodal approach including craniospinal irradiation improves the treatment outcome of high-risk intracranial nongerminomatous germ cell tumors. Int J Radiat Oncol Biol Phys 84: 625-631.
12. Hsieh JL, Lu CS, Huang CL, Shieh GS, Su BH, et al. (2012) Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment. Cancer Lett 321: 36-44.
13. Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59: 1-11.
14. Kubota K, Ichinose Y, Scagliotti G, Spigel D, Kim JH, et al. (2014) Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol 25: 529-536.
15. Walker FE (1993) Paclitaxel (TAXOL): side effects and patient education issues. Semin Oncol Nurs 9: 6-10.
16. Lehoczky O, Bagameri A, Udvary J, Pulay T (2001) Side-effects of paclitaxel therapy in ovarian cancer patents. Eur J Gynaecol Oncol 22: 81-84.
17. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24-31.
18. Kato H, Oizumi H, Watarai H, Sadahiro M (2013) Long survival case of resected lung cancer after chemotherapy with gefitinib. Kyobu Geka 66: 818-821.
19. Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, et al. (2014) Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res 322: 168-177.
20. Bonomi P (2003) Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer 41 Suppl 1: S43-48.
21. Gray J, Haura E (2014) Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 3: 360-362.
22. Atassi G, Spreafico F, Dumont P, Nayer P, Klastersky J (1980) Antitumoral effect in mice of a new triepoxyde derivative: 1, 3, 5-triglycidyl-s-triazinetrione. Eur J Cancer 16: 1561-1567.
23. Neidhart JA, Derocher D, Grever MR, Kraut EH, Malspeis L (1984) Phase I trial of teroxirone. Cancer Treat Rep 68: 1115-1119.
24. Spreafico F, Atassi G, Filippeschi S, Malfiore C, Noseda S, et al. (1980) A characterization of the activity of alpha-1,3,5-triglycidyl-s-triazinetrione, a novel antineoplastic compound. Cancer Chemother Pharmacol 5: 103-108.
25. Piccart M, Rozencweig M, Dodion P, Cumps E, Crespeigne N, et al. (1981) Phase I clinical trial with alpha 1,3,5-triglycidyl-s-triazinetrione. Eur J Cancer Clin Oncol 17: 1263-1266.
26. Ames MM, Kovach JS, Rubin J (1984) Pharmacological characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans. Cancer Res 44: 4151-4156.
27. Wu FY, Le Pecq JB (1983) Mechanistic studies of a novel antitumor drug, alpha-1,3,5-triglycidyl-s-triazinetrione. Antitumor and cytotoxic effects. Mol Pharmacol 23: 182-189.
28. Nicaise C, Rozencweig M, Crespeigne N, Dodion P, Gerard B, et al. (1986) Phase I study of triglycidylurazol given on a 5-day i.v. schedule. Cancer Treat Rep 70: 599-603.
29. Rubin J, Kovach JS, Ames MM, Moertel CG, Creagan ET, et al. (1987) Phase I study of two schedules of teroxirone. Cancer Treat Rep 71: 489-492.
30. Wang JP, Lin KH, Liu CY, Yu YC, Wu PT, et al. (2013) Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53. Toxicol Appl Pharmacol 273: 110-120.
31. Peppin L, McEwing R, Carvalho GR, Ogden R (2008) A DNA-based approach for the forensic identification of Asiatic black bear (Ursus thibetanus) in a traditional Asian medicine. J Forensic Sci 53: 1358-1362.
32. Xiao PG, Liu Y (2003) Several strategic consideration for the modernization of Chinese materia medica. Yao Xue Xue Bao 38: 485-486.
33. Schumacher HR (2008) West meets east--observations on integrative medicine in rheumatology from the USA. Chin J Integr Med 14: 165-166.
34. Grace S, Higgs J (2010) Integrative medicine: enhancing quality in primary health care. J Altern Complement Med 16: 945-950.
35. Boon HS, Kachan N (2008) Integrative medicine: a tale of two clinics. BMC Complement Altern Med 8: 32-39.
36. Li J, Lin HS (2011) Integrative medicine: a characteristic China model for cancer treatment. Chin J Integr Med 17: 243-245.
37. Li J, Li L, Liu R, Lin HS (2012) Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology. Chin J Integr Med 18: 730-736.
38. Jia Y, Guan Q, Guo Y, Du C (2012) Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola. Phytother Res 26: 812-819.
39. Xu L, Feng JM, Li JX, Zhu JM, Song SS, et al. (2013) Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. Cell Death Dis 4: e905.
40. Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2: 143-148.
41. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
42. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Di Maria MV, Veve R, et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807.
43. Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, et al. (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15: 28-32.
44. Bunn PA, Jr., Franklin W (2002) Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 29: 38-44.
45. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246.
46. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158.
47. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 22: 3238-3247.
48. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
49. Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, et al. (2005) Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47: 129-138.
50. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
51. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769.
52. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377.
53. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, et al. (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226-235.
54. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, et al. (2011) Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17: 2260-2269.
55. Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, et al. (2011) Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 56: 275-284.
56. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, et al. (2013) The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer 133: 505-513.
57. Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE (2014) PTEN function: the long and the short of it. Trends Biochem Sci 39: 183-190.
58. Shi Y, Wang J, Chandarlapaty S, Cross J, Thompson C, et al. (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 21: 522-527.
59. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
60. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, et al. (2012) Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 181: 401-412.
61. McConechy MK, Ding J, Senz J, Yang W, Melnyk N, et al. (2014) Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 27: 128-134.
62. Nagy R, Ganapathi S, Comeras I, Peterson C, Orloff M, et al. (2011) Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid 21: 505-510.
63. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, et al. (2000) PIK3CA as an oncogene in cervical cancer. Oncogene 19: 2739-2744.
64. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102.
65. Li H, Zeng J, Shen K (2014) PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet 290: 1067-1078.
66. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, et al. (2014) The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch 465: 25-33.
67. Tasian SK, Teachey DT, Rheingold SR (2014) Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front Oncol 4: 108-115.
68. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, et al. (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059.
69. Fan QW, Weiss WA (2012) Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol Biol 821: 349-359.
70. Chang L, Graham PH, Hao J, Ni J, Bucci J, et al. (2013) Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 4: e875.
71. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104: 16158-16163.
72. Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18: 17-25.
73. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389.
74. Nishitani S, Horie M, Ishizaki S, Yano H (2013) Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin. PLoS One 8: e82346.
75. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S (1995) Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14: 6136-6147.
76. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770-776.
77. Salvesen GS, Dixit VM (1997) Caspases: intracellular signaling by proteolysis. Cell 91: 443-446.
78. Shi Y (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9: 459-470.
79. Kelly GL, Strasser A (2011) The essential role of evasion from cell death in cancer. Adv Cancer Res 111: 39-96.
80. Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11: 255-260.
81. Porter AG, Janicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104.
82. Crous AM, Abrahamse H (2013) Lung cancer stem cells and low-intensity laser irradiation: a potential future therapy? Stem Cell Res Ther 4: 129-136.
83. Passegue E, Rafii S, Herlyn M (2009) Cancer stem cells are everywhere. Nat Med 15: 23-30.
84. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902.
85. He S, Nakada D, Morrison SJ (2009) Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol 25: 377-406.
86. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, et al. (2013) Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 19: 1972-1980.
87. Xi Y, Chen Y (2014) Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis. Cancer Lett 353: 8-16.
88. Zoghbi ME, Altenberg GA (2014) ATP binding to two sites is necessary for dimerization of nucleotide-binding domains of ABC proteins. Biochem Biophys Res Commun 443: 97-102.
89. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806.
90. Long H, Xie R, Xiang T, Zhao Z, Lin S, et al. (2012) Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells 30: 2309-2319.
91. Kim BR, Yoon K, Byun HJ, Seo SH, Lee SH, et al. (2014) The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways. Oncotarget 5: 6540-6551.
92. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, et al. (2013) ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 328: 144-151.
93. Kim IG, Kim SY, Choi SI, Lee JH, Kim KC, et al. (2014) Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene 33: 3908-3917.
94. Liu F, Cao X, Liu Z, Guo H, Ren K, et al. (2014) Casticin suppresses self-renewal and invasion of lung cancer stem-like cells from A549 cells through down-regulation of pAkt. Acta Biochim Biophys Sin 46: 15-21.
95. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, et al. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642.
96. Gires O (2011) Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci 68: 4009-4022.
97. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, et al. (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86: 207-213.
98. Zhang K, Waxman DJ (2010) PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer 9: 319-331.
99. Li Z, Xu X, Huang Y, Ding L, Wang Z, et al. (2012) Swainsonine activates mitochondria-mediated apoptotic pathway in human lung cancer A549 cells and retards the growth of lung cancer xenografts. Int J Biol Sci 8: 394-405.
100. Debatin KM (1997) Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst 89: 750-751.
101. Huppertz B, Frank HG, Kaufmann P (1999) The apoptosis cascade--morphological and immunohistochemical methods for its visualization. Anat Embryol (Berl) 200: 1-18.
102. Herr I, Debatin KM (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614.
103. Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, et al. (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 446: 359-371.
104. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923.
105. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
106. Boehme KA, Kulikov R, Blattner C (2008) p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A 105: 7785-7790.
107. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 9: 714-723.
108. Wang M, Zhang L, Zhao X, Liu J, Chen Y, et al. (2014) Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 36: 651-656.
109. Wang MC, Liang X, Liu ZY, Cui J, Liu Y, et al. (2015) In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in nonsmall cell lung cancer cell lines. Oncol Rep 33: 239-249.
110. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, et al. (1993) Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30-36.
111. Segal-Bendirdjian E, Jacquemin-Sablon A (1995) Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 218: 201-212.
112. Oliva J, French BA, Qing X, French SW (2010) The identification of stem cells in human liver diseases and hepatocellular carcinoma. Exp Mol Pathol 88: 331-340.
113. Yao CJ, Lai GM, Yeh CT, Lai MT, Shih PH, et al. (2013) Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of wnt/ beta -catenin signaling and apoptosis induction. Evid Based Complement Alternat Med 2013: ID146136.
114. Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, et al. (2011) Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer 10: 96-110.
115. Paul S, Kundu R (2013) Antiproliferative activity of methanolic extracts from two green algae, Enteromorpha intestinalis and Rizoclonium riparium on HeLa cells. Daru J Phar Sci 21: 72-83.
116. 林清淵 (2003) 是蟲？是草？不可思議的冬蟲夏草。科學發展。364: 6-9。
117. 郭捷、楊曉琪、程一雄、李寧遠 (2006) 中草藥刺五加對人體抗疲勞功能之作用。中華醫學雜誌。17: 95-102。
118. 劉紹毅 (2005) 紅景天的保健療效與含量成分的比較。中醫內科醫學雜誌。3: 21-25。
119. 巫佩岑 (2014) 鑑定具有清除肺癌幹細胞的藥物。國立台灣師範大學碩士論文。